ASN-007
- Generic Name
- ASN-007
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Erasca, Inc.
- Registration Number
- NCT05279859
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Texas Oncology, Dallas, Texas, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
- Conditions
- Metastatic Pancreatic Ductal AdenocarcinomaMetastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Erasca, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05039177
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer
- Interventions
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Erasca, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04959981
- Locations
- 🇺🇸
Hackensack University Medical Center (John Theurer Cancer Center), Hackensack, New Jersey, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Research Institute, Boston, Massachusetts, United States
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Erasca, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT04866134
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸Sarah Cannon Research Institute (HealthONE), Denver, Colorado, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.